OFATUMUMAB WITH IVAC FOR DLBCL PATIENTS WHO FAILED R‐CHOP AND WERE NOT CANDIDATES FOR HIGH‐DOSE THERAPY AND ASCT ‐ PHASE 2 TRIAL OF THE POLISH LYMPHOMA RESEARCH GROUP (PLRG‐8)
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.111_2631
Abstract: cell lymphoma (DLBCL), salvage chemotherapy prior to autologous stem cell transplant (HSCT) remains the standard approach at relapse. However, there is no consensus salvage regimen and practice varies considerably. Refractory DLBCL or short remission duration… read more here.
Keywords: response; year; disease; toxicity ... See more keywords
IVAC +/- R for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-134607
Abstract: Introduction Part B of the modified Magrath regimen (ifosfamide, etoposide, and cytarabine; IVAC) with or without rituximab (R) is utilized as a standalone regimen in the management of relapsed/refractory Burkitt lymphoma and other non-Hodgkin lymphomas… read more here.
Keywords: refractory cell; ivac; patients received; cell ... See more keywords
How to remove the grey area between ventilator-associated pneumonia and ventilator-associated tracheobronchitis?
Sign Up to like & getrecommendations! Published in 2017 at "Critical Care"
DOI: 10.1186/s13054-017-1754-6
Abstract: We read with great interest the study performed by Paula Ramirez and colleagues [1]. The study included 71 patients with ventilator-associated pneumonia (VAP) and the authors coined a new term called “gradual VAP”. The result… read more here.
Keywords: ventilator associated; gradual vap; ventilator; ivac ... See more keywords